84 Anhydrous Anidulafungin 122Mg Eqv Anidulafungin

證據等級: L5

預測適應症: 0 個

Anidulafungin: Insufficient Data for Repurposing Evaluation

One-Sentence Summary

Anidulafungin is an echinocandin antifungal agent known for treating invasive candidiasis and candidaemia. The current Evidence Pack contains no TxGNN predicted indications and extensive data gaps across regulatory, safety, and mechanistic categories. Evaluation cannot proceed until foundational data is retrieved.

Quick Overview

Item	Content
Original Indication	Not available in current data (anidulafungin is clinically used for invasive candidiasis / candidaemia)
Predicted New Indication	None — `predicted_indications` array is empty
TxGNN Prediction Score	N/A
Evidence Level	L5 (model prediction only; no actual study evidence retrieved)
Singapore Market Status	✗ Not Marketed
Number of Registrations	0
Recommended Decision	Hold

Why is This Prediction Reasonable?

No predicted indications are available in this Evidence Pack, so a repurposing rationale cannot be constructed at this time.

What is known from published pharmacology: anidulafungin inhibits β-1,3-D-glucan synthase, an enzyme essential for fungal cell wall biosynthesis. This mechanism is highly specific to fungi and has no established parallel in mammalian cell biology, which makes broad oncological or inflammatory repurposing hypotheses less intuitive compared to, for example, kinase inhibitors or immunomodulators.

The drug name recorded in the pack — "84% ANHYDROUS ANIDULAFUNGIN 122MG EQV. ANIDULAFUNGIN" — appears to be a raw-material or bulk-ingredient specification rather than a finished product INN entry. This may have caused the TxGNN pipeline to fail drug-name normalisation, resulting in zero prediction output. Resolving the name to the standard INN anidulafungin (DrugBank: DB04834) before re-running the pipeline is the most likely fix.

Clinical Trial Evidence

Currently no related clinical trials were retrieved for a predicted indication, as predicted_indications is empty.

Literature Evidence

Currently no related literature is available for a predicted indication.

Singapore Market Information

Anidulafungin holds no product registrations in Singapore at the time of this report.

Authorization Number	Product Name	Dosage Form	Approved Indication
—	—	—	No records found

Safety Considerations

Please refer to the package insert for safety information. All safety fields in this Evidence Pack are marked as data gaps:

Key warnings: not retrieved
Contraindications: not retrieved
Drug-drug interactions: query returned no results

The DrugBank query did return one result (result_count: 1), but the data was not propagated into the pack. Re-running the DrugBank extraction step should recover MOA, warning, and interaction data.

Conclusion and Next Steps

Decision: Hold

Rationale: The TxGNN pipeline returned zero predicted indications, most likely because the non-standard drug name string failed INN normalisation. Without a valid prediction, no repurposing evaluation can proceed.

To proceed, the following is needed:

Resolve the drug name — Map "84% ANHYDROUS ANIDULAFUNGIN 122MG EQV. ANIDULAFUNGIN" to the standard INN anidulafungin (DrugBank ID: DB04834) and re-run the TxGNN pipeline.
Retrieve MOA data — Pull mechanistic data from DrugBank (query already returned 1 result; extraction step needs to be re-executed).
Retrieve safety data — Download the Singapore HSA or reference-market package insert PDF and parse key warnings and contraindications (Data Gap DG001).
Re-run the full evidence pipeline — Once a valid predicted indication is available, re-collect ClinicalTrials.gov and PubMed evidence for that indication pair.
Confirm Singapore registration intent — Since anidulafungin is currently unregistered in Singapore, confirm whether the repurposing study requires a new NDA or is intended for compassionate / named-patient use.
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.